Dss, Inc. (NYSE: DSS)

DSS, Inc. is a diversified holding company operating across four distinct business segments, primarily focused on packaging, biotechnology, commercial lending, and securities and investment management. The company leverages its subsidiaries to drive innovation, expand market reach, and generate revenue through a mix of manufacturing, research and development, financial services, and investment activities. With operations spanning North America and Asia, DSS aims to capitalize on emerging opportunities in high-growth industries while maintaining a disciplined approach to capital allocation and operational efficiency.

DSS, Inc. generates revenue through the sale of custom packaging solutions, licensing of biotechnology intellectual property, commercial lending services, and securities trading and investment management. Its packaging segment supplies folding cartons, mailers, and security printing products to industries such as pharmaceuticals, consumer goods, and direct marketing. The biotechnology division monetizes patented technologies through licensing agreements and partnerships, while the commercial lending arm provides financing solutions to businesses. The securities and investment management segment earns fees from broker-dealer activities, real estate investment trusts, and advisory services.

The company operates through the following segments.

• Product Packaging: This segment, led by wholly owned subsidiary Premier Packaging Corporation, specializes in custom paperboard and fiber-based packaging solutions. It serves industries including pharmaceuticals, nutraceuticals, consumer goods, and direct marketing, offering folding cartons, security printing, and intelligent packaging. The division also focuses on sustainability initiatives and expanding into high-margin sectors such as medical device and food and beverage packaging.

• Biotechnology: The biotechnology segment is dedicated to research and development of healthcare-related products, including therapeutic drug platforms, sugar substitutes, and antimicrobial technologies. It holds multiple patents and pending applications for innovations such as LineBacker, a multi-faceted therapeutic platform, and 3F, a botanical compound with insect repellent and antimicrobial properties. Revenue is generated through licensing, co-development, and joint ventures with external partners.

• Commercial Lending: Operated through American Pacific Financial, Inc., this segment provides commercial financing solutions, including business lines of credit, land development financing, inventory financing, and third-party loan servicing. It targets businesses in the United States and select Asian markets, offering tailored financial services to support growth and operational needs.

• Securities and Investment Management: This segment encompasses broker-dealer activities, investment advisory services, and real estate investment trusts. It includes DSS Securities, Inc. and Sentinel Brokers Company, a FINRA-registered broker-dealer, as well as AMRE, a medical real estate investment trust. The division competes in capital markets, facilitating securities offerings and managing institutional and retail investor assets.

DSS, Inc. competes in fragmented and highly competitive industries, where its position varies by segment. In product packaging, it faces established players like WestRock Company and Graphic Packaging Holding Company, differentiating itself through customization, sustainability, and regulatory compliance. The biotechnology segment competes with research institutions and biotech firms, leveraging its intellectual property portfolio and strategic partnerships to drive innovation. In commercial lending, DSS contends with traditional banks and investment firms, focusing on niche financing solutions for underserved markets. The securities and investment management segment competes with broker-dealers, REITs, and private equity firms, emphasizing its integrated service offerings and regulatory expertise. The company’s competitive advantages include its diversified business model, patented technologies, and disciplined growth strategy.

The customer base of DSS, Inc. spans multiple industries, with a concentration in packaging, healthcare, and financial services. In 2025, one customer accounted for approximately 29% of consolidated revenue, while in 2024, two customers represented 22% and 13% of revenue, respectively. The product packaging segment serves pharmaceutical, nutraceutical, consumer goods, and direct marketing companies. The biotechnology division collaborates with licensing partners and healthcare firms. Commercial lending clients include businesses requiring financing for development, inventory, or equipment. The securities and investment management segment caters to institutional and retail investors seeking brokerage, advisory, and real estate investment opportunities.